HIKAL
|
The Current P/E Ratio of HIKAL is 291.16.
| Share Price | ₹238.5 | Dec 17,2025 |
| Market Cap | ₹2,940.7 Cr | |
| Earnings-TTM | ₹10.1 Cr | TTM-Consolidated Results |
| Price/Earnings | 291.16x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of HIKAL
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹2,940.7 Cr] as on Dec 17,2025
(/) Earnings [ ₹10.1 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 291.16x ]
Thus, for HIKAL , the investors are currently willing to pay 291.16 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of HIKAL !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of HIKAL over the last five years.
Historical PE (Price/Earnings) ratio chart of HIKAL
PE Ratio Performance Analysis for HIKAL
- HIKAL 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 37.99x.
- HIKAL 's operated at median p/e ratio of 44.34x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, HIKAL 's p/e ratio peaked in Mar2025 at 54.42x.
- HIKAL 's p/e ratio hit its five-year low in Mar2021 of 13.29x.
How does HIKAL 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| HIKAL | 10.10 | 291.16 | 2,940.7 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 40.95 | 430,705.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 67.24 | 167,091.0 |
| CIPLA LTD | 5,453.86 | 22.17 | 120,919.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 59.61 | 127,555.0 |
| DR REDDYS LABORATORIES LTD | 5,721.40 | 18.56 | 106,165.0 |
| MANKIND PHARMA LTD | 1,767.06 | 49.30 | 87,110.1 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 18.58 | 92,407.5 |
| LUPIN LTD | 4,347.53 | 22.20 | 96,528.4 |
| AUROBINDO PHARMA LTD | 3,447.75 | 20.10 | 69,292.5 |
| ABBOTT INDIA LTD | 1,508.95 | 38.95 | 58,778.2 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs HIKAL 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.56x |
| Max industry PE | 291.16x |
| Median industry PE | 38.95x |
| Average industry PE | 58.98x |
You may also like the below Video Courses